Replimune Group short interest was 56.4% of the float on May 15th, according to new data we received from Benzinga. Short interest totaled 23,657,005 shares, which was an increase of 11.81% from April 30th.
It is estimated that it would take 2.83 days for short sellers to buy back their shares, with current trading volumes.
Replimune Group Hedge Fund Activity
We have seen 110 institutional investors add shares of Replimune Group stock to their portfolio, and 93 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUVRETTA CAPITAL MANAGEMENT, LLC added 4,185,798 shares (+11615.0%) to their portfolio in Q1 2026, for an estimated $32,021,354
- TANG CAPITAL MANAGEMENT LLC removed 3,400,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $33,048,000
- BRAIDWELL LP removed 2,750,092 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $26,730,894
- D. E. SHAW & CO., INC. added 2,171,547 shares (+538.2%) to their portfolio in Q4 2025, for an estimated $21,107,436
- GOLDMAN SACHS GROUP INC added 1,619,180 shares (+246.0%) to their portfolio in Q1 2026, for an estimated $12,386,727
- COMMODORE CAPITAL LP removed 1,425,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $10,901,250
- ROSALIND ADVISORS, INC. removed 1,410,497 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $10,790,302
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Replimune Group Insider Trading Activity
Replimune Group insiders have traded $REPL stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $REPL stock by insiders over the last 6 months:
- CHRISTOPHER SARCHI (Chief Commercial Officer) has made 0 purchases and 3 sales selling 27,126 shares for an estimated $206,765.
- SUSHIL PATEL (Chief Executive Officer) sold 37,324 shares for an estimated $189,605
- PHILIP ASTLEY-SPARKE sold 17,657 shares for an estimated $89,697
- KONSTANTINOS XYNOS (Chief Medical Officer) sold 14,023 shares for an estimated $71,236
- ANDREW SCHWENDENMAN (Chief Accounting Officer) sold 7,894 shares for an estimated $40,101
- EMILY LUISA HILL (Chief Financial Officer) sold 7,812 shares for an estimated $39,684
- KAPIL DHINGRA sold 3,169 shares for an estimated $32,957
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Replimune Group Analyst Ratings
Wall Street analysts have issued reports on $REPL in the last several months. We have seen 0 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Underweight" rating on 04/13/2026
- HC Wainwright & Co. issued a "Sell" rating on 04/13/2026
To track analyst ratings and price targets for Replimune Group, check out Quiver Quantitative's $REPL forecast page.
Replimune Group Price Targets
Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Robert Driscoll from Wedbush set a target price of $6.0 on 06/01/2026
- Roger Song from Jefferies set a target price of $2.0 on 04/13/2026
- Jonathan Chang from Leerink Partners set a target price of $2.0 on 04/13/2026
- Allison Bratzel from Piper Sandler set a target price of $14.0 on 02/05/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
